For a patient on atorvastatin 20 mg daily and fenofibrate 54 mg daily with triglycerides 241 mg/dL, non‑HDL cholesterol 147 mg/dL, and LDL cholesterol 101 mg/dL, what medication changes are recommended?

Increase Atorvastatin to 40-80 mg Daily

Your patient requires intensification of statin therapy to achieve guideline-directed LDL-C and non-HDL-C targets, with atorvastatin dose escalation being the most appropriate next step. Continue fenofibrate 54 mg daily as adjunctive therapy for the persistent hypertriglyceridemia.

Current Lipid Status Analysis

Your patient's lipid panel reveals:

• LDL-C 101 mg/dL - above target for most cardiovascular risk categories
• Non-HDL-C 147 mg/dL - significantly above target (should be <130 mg/dL when TG 200-499 mg/dL)
• Triglycerides 241 mg/dL - elevated, requiring non-HDL-C target of <130 mg/dL 1, 2, 3

The current regimen of atorvastatin 20 mg is insufficient. This is a moderate-intensity statin dose that typically reduces LDL-C by 30-49% 4. The fenofibrate is appropriately addressing triglycerides but cannot compensate for inadequate statin dosing.

Recommended Medication Changes

Primary Action: Escalate Atorvastatin

Increase atorvastatin from 20 mg to 40 mg daily immediately, with consideration for 80 mg if 40 mg proves insufficient after 4-6 weeks 5, 6.

• Atorvastatin 40 mg is high-intensity therapy, reducing LDL-C by ≥50% 4
• Atorvastatin 80 mg provides maximal LDL-lowering (the highest dose available) 7
• This dose escalation is safe when combined with fenofibrate at the current dose 7, 8

Continue Fenofibrate 54 mg Daily

Maintain fenofibrate 54 mg daily - this is already addressing the triglyceride component appropriately 1, 2, 3. The combination of statin plus fibrate is specifically recommended for patients with triglycerides 200-499 mg/dL to achieve non-HDL-C targets 1, 2, 3.

Target Goals

Based on cardiovascular risk stratification:

• If very high risk (established ASCVD): LDL-C <55 mg/dL (1.4 mmol/L), non-HDL-C <100 mg/dL 6
• If high risk (diabetes, multiple risk factors): LDL-C <70-100 mg/dL, non-HDL-C <130 mg/dL 1, 2, 3, 9
• For all patients with TG 200-499 mg/dL: non-HDL-C <130 mg/dL 1, 2, 3

Monitoring and Follow-up

• Recheck lipid panel in 4-6 weeks after dose adjustment 5, 7
• Monitor for myopathy symptoms (muscle pain, weakness) - though risk is low with this combination when statin doses are kept reasonable 7, 8
• Check CK only if symptoms develop 10

If Targets Still Not Met After Atorvastatin Escalation

Should atorvastatin 40-80 mg plus fenofibrate 54 mg fail to achieve targets:

1. Add ezetimibe 10 mg daily - provides additional 20-25% LDL-C reduction 6, 4
2. Consider bempedoic acid if statin intolerance develops 5, 6
3. Consider PCSK9 inhibitor for very high-risk patients not at goal on maximal statin + ezetimibe 5, 6

Critical Safety Considerations

The combination of high-dose statin plus fibrate increases myopathy risk 1, 2, 3, 7. However:

• This risk is acceptable when using atorvastatin (not simvastatin) with fenofibrate (not gemfibrozil) 7, 8
• Avoid atorvastatin 80 mg if patient has additional myopathy risk factors (age ≥65, renal impairment, hypothyroidism) 7
• Never use gemfibrozil with statins - fenofibrate is the appropriate fibrate choice 11, 7

Why Not Other Options?

Switching to fenofibrate monotherapy: Inappropriate - would worsen LDL-C control, as fibrates have minimal effect on LDL-C 1, 2, 3

Adding ezetimibe before maximizing statin: Premature - guidelines recommend maximizing statin dose first 5, 6, 4

Reducing either medication: Counterproductive - both lipid abnormalities require treatment to reduce cardiovascular risk 1, 2, 3

The evidence strongly supports that statin intensification is the cornerstone of therapy, with fenofibrate serving as appropriate adjunctive therapy for the mixed dyslipidemia pattern 1, 2, 3, 9, 3.